Creating the Future with Biomolecules: Investment Executed in Epsilon Molecular Engineering
Miraidoor has invested in Epsilon Molecular Engineering, a startup from Saitama University, through a fund established in partnership with regional financial institutions in Saitama Prefecture.
📋 Article Processing Timeline
- 📰 Published: May 30, 2026 at 00:00
- 🔍 Collected: May 30, 2026 at 21:17 (21h 17m after Published)
- 🤖 AI Analyzed: May 30, 2026 at 21:19 (2 min after Collected)
Miraidoor Co., Ltd. (Headquarters: Minato-ku, Tokyo; Chairman and President: Daisuke Sawada; hereinafter 'Miraidoor') announces that it has executed an investment in Epsilon Molecular Engineering Co., Ltd. (Headquarters: Saitama City, Saitama Prefecture; President: Naoto Nemoto; hereinafter 'Epsilon Molecular Engineering') through the Saitama Shibusawa MIX Innovation Creation Support Investment Limited Partnership, which was established in collaboration with Saitama Prefecture, the Japan Finance Corporation (JFC), and regional financial institutions in Saitama Prefecture. This project is a coordinated investment and financing involving Saitama Resona Bank and JFC.
About the Investment Target:
Epsilon Molecular Engineering is a startup from Saitama University possessing advanced biotechnology. Conventionally, antibody acquisition relied primarily on animals. The company leverages 'artificial libraries' that do not use animals and its proprietary screening method, 'cDNA display technology,' to enable faster, more accurate acquisition of diverse antibodies in an animal-free manner. It holds a particular advantage in the domain of 'VHH antibodies' derived from the Camelidae family, which are drawing attention as next-generation antibodies. Recently, the company also plans to enter the screening of standard IgG monoclonal antibodies. Through animal-free antibody generation, the company aims to achieve the societal implementation of various biomolecules, including VHH, in a wide range of fields such as pharmaceuticals, in vitro diagnostics, and research reagents.
Corporate Name: Epsilon Molecular Engineering Co., Ltd.
President: Naoto Nemoto
Headquarters: Room 208, Open Innovation Center Research Building, Saitama University, 255 Shimo-Okubo, Sakura-ku, Saitama City, Saitama Prefecture
Establishment: August 2016
URL: https://www.epsilon-mol.co.jp/
About the Saitama Shibusawa MIX Innovation Creation Support Fund:
This fund was established jointly by Miraidoor and regional financial institutions in Saitama Prefecture, in collaboration with the Saitama Prefectural Government and JFC. It aims to support the sustainable development of regional industries and the creation of new industries and innovations by providing capital to companies in the startup or second-startup phase, and those facing business succession challenges.
About Miraidoor:
Miraidoor focuses on 'Regional Revitalization Funds' for regional startups, 'CVC Funds' for corporate open innovation, and 'Theme-based Funds' for specific industry activation. Beyond capital, it provides support for business development, human resource training, and business consulting to ensure long-term business continuity.
Corporate Name: Miraidoor Co., Ltd.
Chairman and President: Daisuke Sawada
Headquarters: 1-9-9 Roppongi, Minato-ku, Tokyo
URL: https://www.fvc.co.jp/
About the Investment Target:
Epsilon Molecular Engineering is a startup from Saitama University possessing advanced biotechnology. Conventionally, antibody acquisition relied primarily on animals. The company leverages 'artificial libraries' that do not use animals and its proprietary screening method, 'cDNA display technology,' to enable faster, more accurate acquisition of diverse antibodies in an animal-free manner. It holds a particular advantage in the domain of 'VHH antibodies' derived from the Camelidae family, which are drawing attention as next-generation antibodies. Recently, the company also plans to enter the screening of standard IgG monoclonal antibodies. Through animal-free antibody generation, the company aims to achieve the societal implementation of various biomolecules, including VHH, in a wide range of fields such as pharmaceuticals, in vitro diagnostics, and research reagents.
Corporate Name: Epsilon Molecular Engineering Co., Ltd.
President: Naoto Nemoto
Headquarters: Room 208, Open Innovation Center Research Building, Saitama University, 255 Shimo-Okubo, Sakura-ku, Saitama City, Saitama Prefecture
Establishment: August 2016
URL: https://www.epsilon-mol.co.jp/
About the Saitama Shibusawa MIX Innovation Creation Support Fund:
This fund was established jointly by Miraidoor and regional financial institutions in Saitama Prefecture, in collaboration with the Saitama Prefectural Government and JFC. It aims to support the sustainable development of regional industries and the creation of new industries and innovations by providing capital to companies in the startup or second-startup phase, and those facing business succession challenges.
About Miraidoor:
Miraidoor focuses on 'Regional Revitalization Funds' for regional startups, 'CVC Funds' for corporate open innovation, and 'Theme-based Funds' for specific industry activation. Beyond capital, it provides support for business development, human resource training, and business consulting to ensure long-term business continuity.
Corporate Name: Miraidoor Co., Ltd.
Chairman and President: Daisuke Sawada
Headquarters: 1-9-9 Roppongi, Minato-ku, Tokyo
URL: https://www.fvc.co.jp/
FAQ
株式会社Epsilon Molecular Engineeringはどのような企業ですか？
埼玉大学発のスタートアップで、動物を使わない「人工ライブラリ」と独自の「cDNAディスプレイ技術」を用いたアニマルフリーの抗体生成技術を強みとしています。
今回の投資の目的は何ですか？
地域産業の持続的な発展や新たな産業・イノベーションの創出、およびバイオ分子の社会実装を目指すものです。
誰が投資を実行しましたか？
ミライドア株式会社が、埼玉県、日本政策金融公庫と連携して設立した「埼玉県渋沢MIXイノベーション創出支援ファンド」を通じて投資を実行しました。
協調投融資に関わった金融機関はどこですか？
株式会社埼玉りそな銀行と日本政策金融公庫が協調投融資を行っています。
Epsilon Molecular Engineeringの主な技術的優位性は何ですか？
アニマルフリーの環境下で、より速く正確に、多様な抗体（特にVHH抗体）を取得できる「cDNAディスプレイ技術」が強みです。